Gary M. Owens Sells 21,000 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CEO Gary M. Owens sold 21,000 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the transaction, the chief executive officer now owns 43,337 shares in the company, valued at approximately $5,369,887.67. The trade was a 32.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Mesa Laboratories Stock Performance

Shares of MLAB opened at $125.42 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. The firm has a 50-day moving average of $137.74 and a 200-day moving average of $129.29. The company has a market cap of $681.53 million, a PE ratio of -2.71 and a beta of 0.82. Mesa Laboratories, Inc. has a one year low of $83.68 and a one year high of $155.12.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. As a group, equities analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 17th. Shareholders of record on Friday, February 28th were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend was Friday, February 28th. Mesa Laboratories’s dividend payout ratio is -1.38%.

Hedge Funds Weigh In On Mesa Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC boosted its holdings in shares of Mesa Laboratories by 34.1% during the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 100 shares during the period. Quantbot Technologies LP acquired a new stake in Mesa Laboratories during the third quarter worth approximately $70,000. Amundi boosted its holdings in shares of Mesa Laboratories by 81.6% during the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier’s stock worth $91,000 after acquiring an additional 297 shares during the period. Resona Asset Management Co. Ltd. bought a new position in shares of Mesa Laboratories during the fourth quarter worth approximately $92,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Mesa Laboratories during the 4th quarter worth approximately $132,000. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.